# Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome

> **NCT03805581** · PHASE2 · COMPLETED · sponsor: **New York Medical College** · enrollment: 20 (actual)

## Conditions studied

- Sickle Cell Disease
- Acute Chest Syndrome

## Interventions

- **DRUG:** Defibrotide

## Key facts

- **NCT ID:** NCT03805581
- **Lead sponsor:** New York Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-12
- **Primary completion:** 2022-07-01
- **Final completion:** 2023-11-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03805581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03805581, "Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03805581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*